Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, announced that primary and secondary endpoints were not met in Novelos' pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) with its...